期刊文献+

腹水AFP,CEA,CA19-9的联合检测 被引量:10

下载PDF
导出
摘要 目的探讨肿瘤标志物AFP、CEA、CA19-9在腹水检测中的联合应用。方法84例腹水患者分成良性腹水组48例和恶性腹水组36例,分别测定腹水中的AFP、CEA、CA19-9的含量。结果恶性腹水组CEA、AFP、CA19-9检测的各单项结果明显大于良性腹水组(P﹤0.001);联合检测与各个单项检测比较灵敏度明显提高(P<0.05)。结论肿瘤标志物的检测是早期发现肿瘤的重要手段。临床检测CEA、AFP、CA19-9对腹水进行良、恶性判别有重要意义,联合检测将明显提高灵敏度。
出处 《实验与检验医学》 CAS 2009年第4期378-378,380,共2页 Experimental and Laboratory Medicine
  • 相关文献

参考文献6

二级参考文献48

  • 1柳江,李虹星,张欣,克比努,王芳,陈锐.恶性肿瘤特异性生长因子的测定及其临床应用价值[J].现代肿瘤医学,2005,13(5):697-697. 被引量:2
  • 2Kenemans P, Yedema CA, Bon GG, et al. CA 125 in gynecological pathology-a review. Eur J Obstet Gynecol Reprod Biol, 1993, 49(1-2): 115-124.
  • 3O′Brien TJ, Raymond LM, Bannon GA, et al. New monoclonal antibodies identify the glycoproteincarrying the CA 125 epitope. Am J Obstet Gynecol,1991, 165(6 Pt 1): 1857-1864.
  • 4Kenemans P, van-Kamp GJ, Oehr P, et al. Heterologous double-determinant immunoradiometric assay CA 125 Ⅱ: reliable second-generation immunoassay for determining CA 125 in serum. Clin Chem, 1993, 39(12): 2509-2513.
  • 5Matsuoka Y, Nakashima T, Endo K, et al. Recognition of ovarian cancer antigen CA125 by murine monoclonal antibody produced by immunization of lung cancer cells. Cancer Res, 1987, 47(23): 6335-6340.
  • 6Kunimatsu M, Endo K, Nakashima T, et al. Development of new immunoradiometric assay for CA 125 antigen using two monoclonal antibodies produced by immunizing lung cancer cells. Ann Nucl Med, 1988, 2(2): 73-79.
  • 7陈志军 周爱清 沈军瑾 等.CEA,CA19—9联合测定在消化系统恶性肿瘤诊断和治疗治中的价值[J].江西医药,1999,34:10-10.
  • 8Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecol Oncol 2003;88(1 Pt 2):S152-157
  • 9Guppy AE, Rustin GJ. CA125 response: can it replace the traditional response criteria in ovarian cancer? Oncologist 2002;7:437-443
  • 10Tsuda H, Hashiguchi Y, Nakata S, Deguchi M, Negoro S,Ishiko O, Yamamoto K. The CA125 regression rate to predict overall survival differ between paclitaxel-containing regimen and nonpaclitaxel regimen in patients with advanced ovarian cancer. Int J Gynecol Cancer 2002;12:435-437

共引文献74

同被引文献74

引证文献10

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部